Orthofix Q1 net loss $53.1M; lowers FY2025 net sales guidance to $808-816M

Orthofix Medical Inc.

2025-Q1 EPS reported -$1.35 revenue$193,646,000

Q1 pro forma net sales $189.2M, up 4.3% constant currency YoY; GAAP net loss $53.1M ($1.35/share) vs $36.0M loss year ago.
Non-GAAP pro forma adjusted EBITDA $11.4M (6.0% margin), up 49% vs $7.7M in Q1 2024; adjusted gross margin 70.3%.
Lowered FY2025 net sales guidance to $808-816M (pro forma) from $818-826M; reaffirms adjusted EBITDA $82-86M and positive free cash flow.
U.S. Spine Fixation +4%, BGT +5%, Global Orthopedics constant currency +11% YoY; TrueLok Elevate TBT System received FDA clearance.
Management cites commercial channel optimization causing temporary softness; expects growth to normalize after distributor transitions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.